Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer
- Authors
- Lee, Jeong-Yeon; Joo, Hyeong-Seok; Choi, Hee-Joo; Jin, Sora; Kim, Hyung-Yong; Jeong, Ga-Young; An, Hee Woon; Park, Mi Kyung; Lee, Seung Eun; Kim, Wan-Seop; Son, Taekwon; Min, Kyueng-Whan; Oh, Young-Ha; Kong, Gu
- Issue Date
- Jun-2019
- Publisher
- OXFORD UNIV PRESS INC
- Citation
- JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, v.111, no.6, pp.609 - 619
- Indexed
- SCIE
SCOPUS
- Journal Title
- JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
- Volume
- 111
- Number
- 6
- Start Page
- 609
- End Page
- 619
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/147688
- DOI
- 10.1093/jnci/djy151
- ISSN
- 0027-8874
- Abstract
- Background Resistance to HER2-targeted therapy with trastuzumab still remains a major challenge in HER2-amplified tumors. Here we investigated the potential role of MEL-18, a polycomb group gene, as a novel prognostic marker for trastuzumab resistance in HER2-positive (HER2+) breast cancer. Methods The genetic alteration of MEL-18 and its clinical relevance were examined in multiple breast cancer cohorts including METABRIC (n=1,980), TCGA (n=825), and our clinical specimens (n=213, trastuzumab-treated HER2+ cases). MEL-18 amplification was validated by fluorescence in situ hybridization (FISH) analysis. The MEL-18 effect on trastuzumab response was confirmed by in vitro cell viability assays and an in vivo xenograft experiment (n=7 per group). Gene expression microarray and receptor tyrosine kinase array were performed to identify the trastuzumab resistance mechanism by MEL-18 loss. All statistical tests were two-sided. Results MEL-18 was exclusively amplified in approximately 30-50% of HER2+ breast tumors and was associated with a favorable clinical outcome (disease-free survival: P = .02 in HER2+ cases, METABRIC; P = .04 in patients receiving trastuzumab). In MEL-18-amplified HER2+ breast cancer, MEL-18 depletion induced trastuzumab resistance by increasing ADAM sheddase-mediated ErbB ligand production and receptor heterodimerization. MEL-18 epigenetically silenced ADAM10/17 expression in cooperation with polycomb-repressive complex (PRC) 1 and PRC2. Combination treatment with an ADAM10/17 inhibitor and trastuzumab could overcome MEL-18 loss-mediated trastuzumab resistance in vivo (BT474/shMEL-18 xenograft: trastuzumab, mean [SD] tumor volume = 406.1 [50.1] mm(3), vs trastuzumab + GW280264 30mg/kg, mean [SD] tumor volume = 68.4 [15.6] mm(3), P < .001). Consistently, trastuzumab-treated patients harboring concomitant MEL-18 amplification and low ADAM17 expression showed prolonged relapse-free survival (P = .02 in our cohort, n=213). Conclusion MEL-18 serves to prevent ligand-dependent ErbB heterodimerization and trastuzumab resistance, suggesting MEL-18 amplification as a novel biomarker for HER2+ breast cancer.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 병리학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.